|

Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome

RECRUITINGN/ASponsored by Stephan Eliez
Actively Recruiting
PhaseN/A
SponsorStephan Eliez
Started2023-10-20
Est. completion2026-12-31
Eligibility
Age14 Years – 25 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05664412

Summary

The purpose of this project is to explore the effects of transcranial alternating current stimulation (tACS) in children, adolescents and young adults with a 22q11.2 microdeletion. The main aim of the present research project is to investigate the effects of repeated, individually tuned high-density (HD) tACS on cognition (i.e., WM performance) and related neuroimaging markers in carriers of the 22q11DS. As cognitive deficits, most notably WM impairment, are among the earliest signs of psychotic disorders, interventions during adolescence aimed at reducing cognitive decline in at-risk individuals may prove effective in delaying or even preventing the later emergence of psychotic symptoms.

Eligibility

Age: 14 Years – 25 YearsHealthy volunteers accepted
Inclusion Criteria:

* Confirmed genetic diagnosis of 22q11DS
* Age between 14 and 25 years old
* Willingness to participate
* Informed Consent signed by the subject and/or the caregiver(s)

Exclusion Criteria:

* Epilepsy
* Deep brain stimulation electrodes
* Traumatic brain injury
* Facial metal implants

Conditions3

22Q11 Deletion SyndromeHeart DiseasetACS

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.